Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 5 | Breast Cancer Research

Fig. 5

From: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study

Fig. 5

Representative PDX in vivo paclitaxel response. a, c Clinical response was assessed using radiological imaging. Representative MR imaging results before and after paclitaxel chemotherapy for a paclitaxel clinical responder (patient M01) and a clinical non-responder (patient M13) were shown. b, d Passage 4 tumors were used for the drug tests. Tumor fragments (4 mm3) were transplanted subcutaneously into NOD-SCID mice. Once tumors reached 150–200 mm3, mice were randomized to two groups (n = 6–8/group). Paclitaxel (20 mg/kg) or vehicle was administered i.p. every 3 days for 2 weeks. Tumor size and mice body weight were measured every 3–4 days. Data represents as the mean volume of xenograft tumors ± SEM. Statistical difference was analyzed by Student’s t test. *P > 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Tumor pictures were taken when experiments were terminated and tumor mass was quantified. PDX patient-derived xenograft

Back to article page